Allikmets L H, Rägo L K
Naunyn Schmiedebergs Arch Pharmacol. 1983 Nov;324(3):235-7. doi: 10.1007/BF00503902.
The interaction of Ro 15-1788 (5 mg kg-1 i.p.) a benzodiazepine antagonist, with GABA-ergic drugs muscimol (1.4 mg kg-1 i.p.), fenibut (100 mg kg-1 i.p.) and baclofen (5 mg kg-1 i.p.) was examined in behavioural and biochemical studies in rats. All the above-mentioned GABA-ergic drugs produced motor depression and with the exception of muscimol, where anti-aggressive effect was evident, fenibut and baclofen showed only slight antiaggresive properties. Ro 15-1788 attenuated the motor depression produced by these compounds but potentiated their antiaggressive effect. Moreover, it was found that Ro 15-1788 itself possessed dose-related antiaggressive properties. Fenibut increased, whereas muscimol and Ro 15-1788 decreased, the GABA content in the rat striatum. Ro 15-1788 and all the studied GABA-ergic compounds increased the level of the dopamine metabolite 3,4-dihyroxyphenylacetic acid (DOPAC) in the striatum. In spite of this no further increase of DOPAC was observed after concomitant use of Ro 15-1788 with GABA-ergic drugs. The action of investigated GABA-ergic drugs via GABA receptors linked to benzodiazepine receptors is suggested.
在大鼠的行为学和生物化学研究中，检测了苯二氮䓬拮抗剂Ro 15 - 1788（腹腔注射5毫克/千克）与GABA能药物蝇蕈醇（腹腔注射1.4毫克/千克）、芬氨比妥（腹腔注射100毫克/千克）和巴氯芬（腹腔注射5毫克/千克）之间的相互作用。上述所有GABA能药物均产生运动抑制，除蝇蕈醇有明显的抗攻击作用外，芬氨比妥和巴氯芬仅表现出轻微的抗攻击特性。Ro 15 - 1788减轻了这些化合物产生的确运动抑制，但增强了它们的抗攻击作用。此外，还发现Ro 15 - 1788本身具有剂量相关的抗攻击特性。芬氨比妥增加了大鼠纹状体中的GABA含量，而蝇蕈醇和Ro 15 - 1788则降低了该含量。Ro 15 - 1788以及所有研究的GABA能化合物均增加了纹状体中多巴胺代谢产物3,4 - 二羟基苯乙酸（DOPAC）的水平。尽管如此，Ro 15 - 1788与GABA能药物联合使用后，未观察到DOPAC水平的进一步升高。提示所研究的GABA能药物通过与苯二氮䓬受体相连的GABA受体发挥作用。
